4-Fluoro-2-nitrobenzoic acid | CAS:394-01-4

We serve 4-Fluoro-2-nitrobenzoic acid CAS:394-01-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Fluoro-2-nitrobenzoic acid

Chemical Name:4-Fluoro-2-nitrobenzoic acid
CAS.NO:394-01-4
Synonyms:4-Fluoro-2-nitrobenzoic acid
4-Fluoro-2-Nitrobenzoicacid
4-Fluor-2-nitro-benzoesaeure
2-nitro-4-fluorobenzoic acid
benzoic acid,4-fluoro-2-nitro
 
Physical and Chemical Properties:
Density 1.6±0.1 g/cm3
Boiling Point 343.8±27.0 °C at 760 mmHg
Melting Point 147-148°C
Molecular Formula C7H4FNO4
Molecular Weight 185.109
Flash Point 161.7±23.7 °C
 
Specification:
Appearance:White to light yellow crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 4-Fluoro-2-nitrobenzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,benzoic acid,4-fluoro-2-nitro physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Fluoro-2-Nitrobenzoicacid Use and application,4-Fluoro-2-nitrobenzoic acid technical grade,usp/ep/jp grade.


Related News: They have also voiced frustrations about patients from mainland China hiding their travel and medical history, potentially endangering other patients.2,3-Di-O-para-toluoyl-D-tartaric acid manufacturer Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.[3-(Dimethylamino)propyl]triphenylphosphonium bromide hydrobromide supplier Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.triethoxy(propyl)silane vendor Three more patients have been confirmed infected with coronavirus in South Korea, bringing the country’s total to 15, the South Korean Centers for Disease Control and Prevention (KCDC) announced in a press release.Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037.